Urszula Doboszewska, Katarzyna Socała, Mateusz Pieróg, Dorota Nieoczym, Jan Sawicki, Małgorzata Szafarz, Kinga Gawel, Anna Rafało-Ulińska, Adam Sajnóg, Elżbieta Wyska, Camila V Esguerra, Bernadeta Szewczyk, Marzena Maćkowiak, Danuta Barałkiewicz, Katarzyna Mlyniec, Gabriel Nowak, Ireneusz Sowa, Piotr Wlaź
The pharmacological activation of the GPR39 receptor has been proposed as a novel strategy for treating seizures; however, this hypothesis has not been verified experimentally. TC-G 1008 is a small molecule agonist increasingly used to study GPR39 receptor function but has not been validated using gene knockout. Our aim was to assess whether TC-G 1008 produces anti-seizure/anti-epileptogenic effects in vivo and whether the effects are mediated by GPR39. To obtain this goal we utilized various animal models of seizures/epileptogenesis and GPR39 knockout mice model...
April 25, 2023: Cellular and Molecular Life Sciences: CMLS